Introduction to interstitial lung diseases
description
Transcript of Introduction to interstitial lung diseases
![Page 1: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/1.jpg)
Introduction to interstitial lung diseases
By/ Mahmoud essam el dien
![Page 2: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/2.jpg)
Interstitial lung disease, or diffuse parenchymal lung disease
The interstitial lung diseases (ILDs) represent a large number of conditions that involve the parenchyma of the lung—the alveoli, the alveolar epithelium, the capillary
endothelium, and the spaces between these structures, as well as the perivascular and lymphatic tissues.
![Page 3: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/3.jpg)
The term "interstitial" is misleading since the pathologic process usually begins with injury to the alveolar epithelial or capillary endothelial cells
This heterogeneous group of disorders is classified together because of similar clinical, physiologic, or pathologic manifestations.
![Page 4: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/4.jpg)
classification
![Page 5: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/5.jpg)
classification
One useful approach to classification is to separate the ILDs into two groups based on the major underlying histopathology:
(1) Those with a predominantly granulomatous reaction in interstitial or vascular areas
(2) Those associated with predominant inflammation and fibrosis.
![Page 6: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/6.jpg)
GRANULOMATOUS LUNG DISEASE
This process is characterized by an accumulationof T lymphocytes, macrophages, and epithelioid
cells organized into discrete structures (granulomas) in the lung parenchyma.
The granulomatous lesions can progress to fibrosis. Many patients with granulomatous lung disease remain free of severe impairment of lung function, or, when symptomatic, they improve after treatment.
![Page 7: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/7.jpg)
INFLAMMATION AND FIBROSIS
The initial insult is an injury to the epithelial surface causing inflammation in the air spaces and alveolar walls.
If the disease becomes chronic, inflammation spreads to adjacent portions of the interstitium and vasculature and eventually causes interstitial fibrosis.
.
![Page 8: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/8.jpg)
cont’d
The development of irreversible scarring (fibrosis) of alveolar walls, airways, or vasculature is the most feared outcome in all of these conditions because it is often progressive and leads to significant derangement of ventilatory function and gas exchange
![Page 9: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/9.jpg)
Risk groups
Age
![Page 10: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/10.jpg)
• Gender
• Smoking history
• Duration of illness
• Prior medication use
• Environmental exposures
![Page 11: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/11.jpg)
![Page 12: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/12.jpg)
CLINICAL PRESENTATION
— Patients with ILD commonly come to clinical attention in one of the following ways:
• With symptoms of progressive breathlessness with dyspnea or a persistent nonproductive cough.
• With an abnormal chest radiograph. • With pulmonary symptoms associated with another disease,
such as a connective tissue disease With lung function abnormalities.
![Page 13: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/13.jpg)
LABORATORY STUDIES
Serologic studies should be obtained if clinically indicated by :
features suggestive of a connective tissue disease (antinuclear antibodies, rheumatoid factor),
environmental exposure or systemic vasculitis (antineutrophil cytoplasmic antibodies, anti-glomerular basement membrane antibody).
![Page 14: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/14.jpg)
Chest radiography--- normal in as many as 10 percent of patients with some forms of ILD.
Computed tomography--- increasingly important method for the evaluation of diffuse pulmonary parenchymal disease.
Serum markers--- including surfactant protein A and B (SP-A, SP-B).
![Page 15: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/15.jpg)
Pulmonary function testing --- Complete lung function testing (spirometry, lung volumes, diffusing capacity) should be obtained.
Measurement of lung function is helpful in assessing the severity of lung involvement in patients with ILD.
![Page 16: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/16.jpg)
• Three diagnostic techniques are in common use: bronchoalveolar lavage, transbronchial biopsy, and surgical lung biopsy.
• Bronchoalveolar lavage may provide a specific diagnosis in cases of infection, particularly with mycobacteria, or when cytologic examination reveals the presence of malignant cells.
• The findings may be suggestive but not diagnostic.
![Page 17: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/17.jpg)
• Transbronchial biopsy is easily performed. The risks of pneumothorax and hemorrhage are low. However, the tissue specimens recovered are small, sampling error is common.
• Transbronchial biopsy can make a definitive diagnosis of sarcoidosis, lymphangitic spread of carcinoma.
• Transbronchial biopsy cannot establish a specific diagnosis of idiopathic interstitial pneumonia.
![Page 18: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/18.jpg)
Surgical lung biopsy
• Indications for performing a lung biopsy include the following :
• To assess disease activity. • To exclude neoplastic and infectious
processes that occasionally mimic chronic, progressive interstitial disease.
• To establish a definitive diagnosis and predict prognosis before proceeding with therapies which may have serious side effects
![Page 19: Introduction to interstitial lung diseases](https://reader036.fdocuments.in/reader036/viewer/2022062301/5681408e550346895dac1b3d/html5/thumbnails/19.jpg)
Thank you